华丽家族股份有限公司 股票交易异常波动公告 证券代码：600503 证券简称：华丽家族 公告编号：临2025－025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 华丽家族股份有限公司（以下简称"公司"）股票于2025年8月19日、2025 年8月20日连续二个交易日内收盘价格涨幅偏离值累计超过20%。根据《上海证 券交易所交易规则》的有关规定：股票连续三个交易日内收盘价格涨幅偏离值累 计超过20%，属于股票交易异常波动。 ? 经公司自查，并向控股股东、实际控制人核实，截至本公告披露日，除公 司已披露事项外，不存在其他应披露而未披露的重大信息。 ? 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票于2025年8月19日、2025年8月20日连续二个交易日内收盘价格涨幅 偏离值累计超过20%。根据《上海证券交易所交易规则》的有关规定：股票连续 三个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。 二、公司关注并核实的相关情况 针对公司股票交易 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002600 证券简称：领益智造 公告编号：2025-112 债券代码：127107 债券简称：领益转债 广东领益智造股份有限公司 一、股票交易异常波动的情况介绍 广东领益智造股份有限公司（以下简称"公司"）股票于 2025 年 8 月 18 日、 超过 20%，根据深圳证券交易所的有关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票异常波动，公司进行了自查，并对相关事项进行了核查，现将 有关情况说明如下： 大影响的未公开重大信息； （公告编号：2025-089）， （www.cninfo.com.cn）上披露了《2025 年半年度业绩预告》 经公司财务部门初步测算，2025 年半年度公司归属于上市公司股东的净利润为 盈利 90,000 万元–114,000 万元，比上年同期增长 31.57%–66.66%，扣除股权 激励摊销费用归属于上市公司股东的净利润为盈利 104,000 万元–128,000 万元， 比上年同期增长 48.59%–82.88%，扣除非经常性损益后的净利 ...

Core Viewpoint - The stock of Huayi Family Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price deviation exceeding 20% over two consecutive trading days on August 19 and 20, 2025 [2][4]. Group 1: Stock Trading Abnormality - The stock price deviation of Huayi Family Co., Ltd. exceeded 20% over two consecutive trading days, which is significant under the Shanghai Stock Exchange trading rules [2][4]. - If the stock price deviation exceeds 20% for three consecutive trading days, it will be classified as an abnormal trading fluctuation [4]. Group 2: Company Verification and Operations - The company conducted a self-examination and confirmed that its production and operations are normal, with no significant changes in the internal and external environment [5]. - There are no undisclosed major operational information or events that could impact the stock price, including major asset restructuring or significant transactions [6]. Group 3: Media Reports and Market Rumors - Aside from the announcement regarding cash injection into Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. on August 11, 2025, no other media reports or market rumors have been identified that could significantly affect the stock price [7]. Group 4: Shareholding and Pledge Information - As of the announcement date, the controlling shareholder, Shanghai Nanjing (Group) Co., Ltd., holds 114,020,000 shares, accounting for 7.12% of the total share capital, with 90,075,800 shares pledged, representing 5.62% of the total share capital [10]. Group 5: Financial Performance - The company expects a net loss attributable to shareholders of the parent company in the range of -12.5 million to -8.35 million yuan for the first half of 2025, indicating a shift from profit to loss compared to the previous year [11].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 18 to August 20, 2025, indicating abnormal trading activity [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price closed at 33.11 yuan per share as of August 20, 2025, with a recent cumulative increase that surpasses most peers in the industry and the Shanghai Composite Index [2][9]. - The rolling price-to-earnings (P/E) ratio for the company is reported at 338.72, significantly deviating from the industry average P/E ratio of 32.11 for the pharmaceutical manufacturing sector [2][9]. Group 2: Company Operations and Confirmations - The company conducted a self-examination and confirmed that its daily operations remain normal, with no significant changes or major events affecting its business [4][5]. - There are no undisclosed significant matters or ongoing major asset restructuring, share issuance, or other substantial corporate actions as of the announcement date [5][8]. Group 3: Market and Media Influence - The company has not identified any media reports or market rumors that could have significantly impacted its stock price, nor any leaks of undisclosed major information by company personnel [6][7].

Core Viewpoint - The stock of Taihao Technology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from August 18 to August 20, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][4]. Group 1: Stock Trading Abnormality - The stock price deviation reached a cumulative increase of 20% over three consecutive trading days [2][4]. - The company confirmed that its main business and production operations are normal, with no significant changes in market conditions or industry policies [2][5]. Group 2: Company Verification and Major Events - The company is planning to acquire a 27.46% stake in its subsidiary, Taihao Military Industry, through a share issuance [3][7]. - The first major shareholder, Tongfang Co., Ltd., confirmed that there are no undisclosed significant matters related to the company [7][12]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that could significantly impact its stock price [8][9]. Group 4: Board of Directors Statement - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the relevant regulations of the Shanghai Stock Exchange [12].

Core Viewpoint - The company, Yazhen Home Co., Ltd., has experienced a significant stock price fluctuation, leading to a temporary suspension of trading to protect investor interests. The stock will resume trading on August 21, 2025, after a thorough review of its trading activities and financial performance [2][3][13]. Group 1: Stock Trading and Suspension - The company's stock price increased by 33.92% from July 30 to August 6, 2025, significantly deviating from the Shanghai Composite Index and the furniture manufacturing industry [2][3]. - The stock was suspended from trading on August 7, 2025, for a period not exceeding 10 trading days, to conduct a review of the trading situation [3][13]. - The stock will resume trading on August 21, 2025, following the completion of the review [3][13]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total revenue of 202.40 million yuan, with a net loss attributable to shareholders of 116.96 million yuan [4][9]. - The company expects a net loss for the first half of 2025 to be between 39.50 million yuan and 33.00 million yuan [4][9]. - The company has been placed under delisting risk warning since May 6, 2025, due to its financial performance [4][9]. Group 3: Acquisition and Business Development - The company plans to acquire 51% of Guangxi Zirconium Industry Technology Co., Ltd. from Hainan Zirconium Titanium Resources Holdings Group Co., Ltd. for 55.45 million yuan [5][15]. - As of August 20, 2025, the acquisition has been completed, and Guangxi Zirconium has become a subsidiary of the company [5][16]. - The company has initiated the pledge procedures for the acquired shares, which have been successfully registered [18].

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days (August 15, 18, and 19, 2025) [2] - The board of directors confirmed that there are no corrections or supplements needed for previously disclosed information, and the company's current operating conditions are normal without significant changes in the internal or external business environment [2][3] - The company and its controlling shareholders have not engaged in any undisclosed significant matters related to the company during the period of stock price fluctuation [2][3] Group 2 - The board of directors confirmed that there are no undisclosed matters that should have been disclosed according to the Shenzhen Stock Exchange listing rules, nor any related planning, discussions, or agreements that could significantly impact the company's stock price [3] - The company has conducted a self-examination and confirmed compliance with fair information disclosure regulations, indicating no violations [4]

Core Viewpoint - Oulin Bio (688319) experienced a significant stock price increase, with a cumulative rise of over 30% in three consecutive trading days, leading to a classification of abnormal trading activity [1] Company Summary - Oulin Bio confirmed that its daily operations are normal and there have been no significant changes in its business [1] - The company conducted inquiries with its controlling shareholder and actual controller, confirming that there are no undisclosed major information as of the announcement date [1] - The recent stock price increase of Oulin Bio has outpaced most of its industry peers and the Shanghai Composite Index, indicating a potential short-term market overheating risk [1]

Core Viewpoint - *ST Songfa's stock price has experienced significant fluctuations, with a cumulative increase of 15.3% over three trading days, contrasting with the market's 1.88% rise, indicating potential investor interest and market volatility [1] Group 1: Stock Performance - The stock price of *ST Songfa increased by 15.3% from August 18 to August 20, while the overall market rose by 1.88% during the same period [1] - As of the close on August 20, *ST Songfa's stock was priced at 59.3 yuan per share, resulting in a total market capitalization of 575.7 billion yuan [1] Group 2: Company Announcements - The company disclosed that it has not identified any undisclosed significant information aside from what has already been made public [1] - *ST Songfa has undergone a major asset restructuring, with the completion of related transactions expected by May 2025 and the registration of new shares by August 18, 2025 [1] Group 3: Business Transformation - The company's main business has shifted from ceramic manufacturing to the research, development, production, and sales of ships and high-end equipment [1]

Core Viewpoint - The stock of VeriSilicon Limited has experienced significant volatility, with a cumulative price deviation exceeding 30% over three consecutive trading days, but the company confirms that its operations remain stable and there are no undisclosed significant events [1] Group 1: Stock Performance - The stock price of the company has shown abnormal fluctuations, with a cumulative increase of over 30% in the last three trading days [1] - The first major shareholder, VeriSilicon Limited, has confirmed that there are no undisclosed significant information as of the announcement date [1] Group 2: Business Operations - The company reports that all production and operational activities are normal, with no significant changes occurring [1] - As of the end of the first quarter of 2025, the company expects to have an order backlog amounting to 3.025 billion yuan, which represents a 23.17% increase compared to the end of the first quarter of 2025, marking a historical high for the company [1]